Cargando…
Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: Rationale and therapeutic potential
Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary interstitial inflammatory disease of unknown etiology, and is also a sequela in severe patients with the Coronavirus Disease 2019 (COVID-19). Nintedanib and pirfenidone are the only two known drugs which are conditionally recommended for...
Autores principales: | Zhang, Yukun, Lu, Peng, Qin, Huan, Zhang, Yuelin, Sun, Xinru, Song, Xunan, Liu, Jingjing, Peng, Hui, Liu, Yiting, Nwafor, Ebuka Olisaemeka, Li, Jiawei, Liu, Zhidong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836923/ https://www.ncbi.nlm.nih.gov/pubmed/33378971 http://dx.doi.org/10.1016/j.biopha.2020.111072 |
Ejemplares similares
-
Chlorogenic acid: Potential source of natural drugs for the therapeutics of fibrosis and cancer
por: Nwafor, Ebuka-Olisaemeka, et al.
Publicado: (2021) -
Salvianolic acid B dry powder inhaler for the treatment of idiopathic pulmonary fibrosis
por: Lu, Peng, et al.
Publicado: (2022) -
Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016) -
Incidence and Clinical Characteristics of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis
por: Yan, Wei, et al.
Publicado: (2015) -
Idiopathic Pulmonary Fibrosis: A Systemic Disease?
por: Man, Luo, et al.
Publicado: (2017)